Navigation Links
BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award
Date:4/6/2009

Expertise and Technology for the Medical Waste Treatment Market

MOUNTAIN VIEW, Calif., April 6 /PRNewswire/ -- Based on its recent analysis of the medical waste treatment market, Frost & Sullivan recognizes BioMedical Technology Solutions (BMTS), Inc. with the 2009 North American Frost & Sullivan Award for Product Innovation of the Year. The company has outpaced its competitors in product innovation, as evidenced by its introduction of the Demolizer(R) II. This novel system provides a simple and effective solution to biomedical waste management at the point of generation, thereby eliminating the possibility of sharps and red bag biomedical waste being disposed of directly into the environment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Most market participants are reluctant to invest in R&D because the market is not considered big enough to warrant huge expenses on product innovation. However, it was established that in 2007, more than 1.5 billion pounds (or 5 pounds per person) of biomedical waste was generated in the U.S. costing over $3.5 billion to remove and destroy. Such statistics, which prompted BMTS to cash in on the market potential, led to the Demolizer(R) II.

Biomedical waste processed with the Demolizer(R) II is rendered sterile and non-biohazardous. The Demolizer(R) II eliminates the need to store waste on site between pickups, removing the possibility of bacterial growth and thereby, airborne diseases.

It simplifies compliance requirements by automatically storing and printing state and local regulatory data after every process. The technology eliminates all legal liabilities (Cradle to Grave) and provides complete control over biomedical waste disposal requirements.

"The Demolizer II is the best method available to manage biomedical waste disposal requirements," says Frost & Sullivan Shilpa Tiku. "In comparison to traditional hauling methods, the device provides every advantage that a generator could ask for: safety, simplicity, security, and cost savings."

BTMS is looking to expand its market share by evolving into a solutions-based company from being a mere equipment manufacturer. Its technological developments have been widely accepted, encouraging it to adopt an aggressive approach by creating a hybrid support infrastructure - health care sales professionals (HCSP) - to accelerate product awareness and acceptance.

"The Demolizer II system is uniquely designed to provide the optimal biomedical waste management solution in a wide variety of settings such as patient care, veterinary care, public venues, and other applications," notes Ms. Tiku. "With systems in every facet of the medical arena as well as nursing homes, sports stadiums, military bases, emergency response, and hospitality services, BMTS has identified over a million potential customers that could benefit from the Demolizer II in the U.S. alone."

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching and developing a broad line of emerging products and technologies.

About BioMedical Technology Solutions Holdings, Inc.

BioMedical Technology Solutions Holdings, Inc. trades on the OTCBB under the symbol (BMTL) and is located in Englewood, Colorado sells the Demolizer(R) II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer(R) Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the U.S. and a global market five times larger than the U.S. For more information, visit www.bmtscorp.com or call 866-525-2687.

About the Demolizer(R) II

The Demolizer (R) II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer(R) II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 47 states after review by 78 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer(R) II provides a safer, more environmentally GREEN method for biomedical waste disposal.

Safe Harbor for Forward Looking Statements

The statements contained in this press release may include certain projections and forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve a number of risks and uncertainties. Such statements reflect the Company's current views with respect to future events and financial performance. No assurances can be given however, that these events will occur or that such expectations will be achieved and that actual results could differ materially from those described. Actual results of future operations of BioMedical Technology Solutions Holdings, Inc. may differ materially from those indicated by these forward looking statements as a result of various important factors.

    BioMedical Technology Solutions, Inc.
    Don Cox, 866-525-BMTS (2687)

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Jake Wengroff
    210.247.3806
    jake.wengroff@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
3. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
4. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
5. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
6. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
7. American Red Cross Announces New Leader for Biomedical Services
8. New nanotube findings by Stanford researchers give boost to potential biomedical applications
9. Lung Cancer Alliance Urges Inclusion of $5 Billion for Biomedical Research in Economic Stimulus Package
10. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
11. Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... Sideline Products ... for the betterment of both the smaller rider and the horse. Smaller saddles can ... Saddle Sidekick is designed to fit over a properly fitted western saddle so it ...
(Date:12/5/2016)... PA (PRWEB) , ... December ... ... ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced it has ... Supplies ("TCS"). TCS was previously a subsidiary of Chiltern International and ...
(Date:12/5/2016)... Lakes, NJ (PRWEB) , ... December 05, 2016 ... ... recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson ... Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , ...
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina ... of New York was founded by James M. Maisel, MD and has been providing tertiary ... has always followed a legacy of surpassing expectations amongst her peers. Growing up in ...
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. ... of patients who do not do their research and undergo cosmetic dermatology treatments from ... the midst of a renaissance and every other month a new treatment or device ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, 2016 ... has entered into a multi-product marketing agreement with ... seven (7) injectable products. Under the terms of ... products under its label in the ... approved ANDA,s and one tentatively-approved ANDA. The products ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: